1952
Founded
Zydus Lifesciences
A 1952 Ahmedabad founding that grew from a Patel-Modi partnership into a ₹23,000-plus crore Indian pharma player with a domestic generics base, a biosimilars first mover position (adalimumab Exemptia in 2014) and a growing US specialty pipeline.
After the 2022 Cadila Healthcare rename to Zydus Lifesciences and the 2025 acquisition of Agenus' US CDMO sites in Emeryville and Berkeley, the question is whether the combined domestic, biosimilars and US specialty engines stay coordinated as the company moves from a generics-led identity to a biologics-and-specialty one.
Who founded Zydus Lifesciences and when?
The company was founded in 1952 in Ahmedabad as Cadila by Ramanbhai Patel (1925 to 2001), a former L.M. College of Pharmacy lecturer, with his business partner Indravadan Modi. In 1995 the families split; the Patel branch retained what became Cadila Healthcare, renamed Zydus Lifesciences in 2022.
How big is Zydus today?
Per FY2025 results, revenue was about ₹23,241 crore on operating income of about ₹7,058 crore and net income of about ₹4,745 crore. Employees were 25,000-plus as of 2023.
What does Zydus do that other Indian pharma majors do not?
In 2014 it launched the world's first adalimumab biosimilar, Exemptia, at one-fifth the originator price. Saroglitazar (Lipaglyn) was its first research-based new chemical entity. ZyCoV-D received DCGI emergency-use nod in August 2021 as the world's first DNA COVID-19 vaccine.
What was the most defining recent move?
The 2025 acquisition of Agenus' contract manufacturing business including two biologics sites in Emeryville and Berkeley, paired with India commercialisation rights for Agenus' molecules. It deepens the biologics and specialty bench.
Key takeaways
Origin
In 1952, a lecturer at the L.M. College of Pharmacy in Ahmedabad started a pharmaceutical company with a business partner. Ramanbhai Patel and Indravadan Modi founded Cadila, the company that would, four decades later, split into two and become two of India's most recognised pharma names. In 1995, the Patel and Modi families divided the business: the Modi share became Cadila Pharmaceuticals, the Patel share became Cadila Healthcare. The Patel half went on to list on the BSE in February 2000 and to rename itself Zydus Lifesciences in 2022.
From generics to a biosimilars first mover
Zydus' commercial signature is breadth combined with a willingness to lead. The branded generics base grew through organic launches and through acquisitions of German Remedies (2003) and Nikkho do Brasil (2007). The defining moves came in biologics. In 2014, Cadila launched Exemptia, the world's first adalimumab biosimilar, at about one-fifth of the originator price; a strategic statement that biosimilars were not an adjacency but a separate engine. Lipaglyn (saroglitazar), the company's first home-grown new chemical entity, made the same statement in small molecules. ZyCoV-D, the world's first DNA COVID-19 vaccine to receive emergency-use nod from DCGI in August 2021, made it again under pandemic conditions.
Why the commercial engine is the interesting part
By FY2025 Zydus reports revenue of about ₹23,241 crore on operating income of about ₹7,058 crore and net income of about ₹4,745 crore, with 25,000-plus employees per 2023 disclosures. Underneath sit three engines under one P&L: India branded prescription (multi-division detailing into cardiology, gastroenterology, oncology and beyond); regulated-market generics and specialty led by US filings; and a biosimilars-and-innovative-biologics track that runs on multi-year clinical and regulatory cycles. Each engine is fundable; coordinating across them is harder than it looks. The October 2024 USFDA approval for enzalutamide tablets and the 2025 Agenus CDMO acquisition both raised the operational stakes on the biologics side specifically.
The next chapter
The 2025 Agenus deal added two US biologics manufacturing sites in Emeryville and Berkeley and India commercialisation rights for Agenus' molecules. Combined with the existing Exemptia and biosimilar lineup, it makes biologics a material rather than supplementary engine. The question the next four to eight quarters will answer is how cleanly the new US biologics layer integrates with the legacy generics base, and whether the brand and field engine adapts to a higher proportion of specialty and biologics conversation.
It will not be more dashboards. The next advantage is intelligence: every rep on Exemptia or a biosimilar walking in knowing what shifted in this rheumatologist's prescribing this fortnight, every divisional head separating a state-level coverage slip from a competitor move in time to act, every leadership review focused on the two or three biologics-launch and integration decisions that actually move the quarter. The first generation of Indian pharma built access. The second built scale. The next will build intelligent commercial operations. That is the future PharmaOS is built for.
Zydus Lifesciences
1952
Founded
Timeline
Ramanbhai Patel and Indravadan Modi found Cadila in Ahmedabad.
A lecturer-turned-founder bet that becomes the Patel family's pharma platform.
Patel and Modi families split; the Patel family retains Cadila Healthcare.
A clean separation that lets the Patel franchise pursue listed-company scale.
Launches Exemptia, the world's first adalimumab biosimilar, at one-fifth the originator price.
Establishes biosimilars as a strategic vector, not a generics add-on.
Acquires Agenus' US CDMO business, including biologics sites in Emeryville and Berkeley; takes India commercialisation rights for Agenus' molecules.
Moves the company materially up the biologics value curve in regulated markets.
Commercial engine
Therapy areas
Cardiovascular, anti-infectives, gastrointestinal, oncology, women's healthcare and CNS as anchors; biosimilars (adalimumab, trastuzumab and others) plus the OTC and consumer-wellness layer via Zydus Wellness.
Field force
A multi-division Indian field force across branded prescription divisions, plus a US-focused regulated generics and specialty engine; about 25,000-plus employees per 2023 disclosures.
Doctor engagement
Specialist and high-volume prescriber engagement across cardiology, gastroenterology and oncology; biosimilar detailing into rheumatology and oncology specialists.
Flagship brands
Exemptia (adalimumab biosimilar), Lipaglyn (saroglitazar), SoviHep (sofosbuvir) and a wide branded generics base. Acquired franchises through German Remedies (2003) and Nikkho do Brasil (2007).
Distribution
Domestic India footprint plus US generics, Brazil presence via Nikkho, and growing biologics distribution post the 2025 Agenus deal. Three Indian API sites at Ankleshwar, Vadodara and Patalganga.
Execution complexity
Three engines under one P&L: India branded generics, regulated-market generics and specialty, and a biosimilars and innovative-biologics track that runs on different cadence. Integration of US biologics manufacturing now adds a new operating layer.
Stock and event snapshot
LoadingPharmaOS reading
A company moving from a generics-and-biosimilars identity towards a more specialty and biologics one, with the 2025 Agenus CDMO acquisition adding US biologics manufacturing. The decade's question is how quickly the biologics and specialty layer compounds relative to the generics base.
This is market commentary for business and industry analysis only. It is not investment advice, research advice or a recommendation to buy, sell or hold any security.
If it were built today
Every rep detailing Exemptia or a biosimilar to a rheumatologist would walk in already knowing what shifted in that specialist's biosimilar prescribing this fortnight, against which competitor.
Every divisional head across the prescription divisions would see whether a state-level slip was a coverage gap, a stocking issue or a competitor move, with the cause separated before the review.
Every brand manager on Lipaglyn or SoviHep would see whether prescriber adoption was a category dynamic or an execution gap, the same week.
Leadership would act on the two or three coverage, integration and biologics-launch decisions that move the quarter, not review three engines in dashboards.
The PharmaOS point of view
The next advantage in pharma is decision intelligence, not a larger field force or more dashboards.
The first generation of Indian pharma built access. The second built scale. The next will run on commercial intelligence: every rep, manager and brand head acting on the real reason, in time to change the outcome.
Continue
See the operating intelligence layer.
A 20-minute private walkthrough on a slice of your own commercial data. Nothing migrated, nothing stored.
FAQ
No. Independent commentary written only from public sources for business analysis. It implies no endorsement or commercial relationship.
From Zydus' public Q4 and FY25 earnings presentation, the company's audited consolidated results, mainstream coverage of the 2022 rename and the 2025 Agenus deal, and Wikipedia. Sources are listed below.
No. The reading is qualitative business interpretation only. It is not investment, research or trading advice, and no target price or directional call is offered.
Pharma's next advantage is decision intelligence across reps, managers and brands, not a larger field force or more dashboards.
Sources
- 01Wikipedia: Zydus Lifesciences. en.wikipedia.org (accessed 2026-05-19)
- 02Zydus Lifesciences: Q4 and FY25 Earnings Presentation. zyduslife.com (accessed 2026-05-19)
- 03Business Standard: Cadila Healthcare changes name to Zydus Lifesciences (24 February 2022). business-standard.com (accessed 2026-05-19)
- 04Pharmaceutical Technology: Agenus signs agreements for botensilimab and balstilimab with Zydus (4 June 2025). pharmaceutical-technology.com (accessed 2026-05-19)